Ignite Creation Date:
2024-05-05 @ 5:02 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00372788
Status:
COMPLETED
Last Update Posted:
2014-08-13
First Post:
2006-09-05
Brief Title:
AZD6244 Versus Pemetrexed Alimta in Patients With Non-small Cell Lung Cancer Who Have Failed One or Two Prior Chemotherapy Regimen
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Phase II Open Randomised Study to Assess the Efficacy and Safety of AZD6244 Versus Pemetrexed Alimta in Patients With Non-small Cell Lung Cancer Who Have Failed One or Two Prior Chemotherapy Regimen
Status:
COMPLETED
Status Verified Date:
2014-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess the effect and safety of AZD6244ARRY-142886versus pemetrexed in the second or third line treatment of advanced Non-Small Cell Lung Cancer Following baseline assessments a minimum of 64 patients in approximately 5-6 centers from the US will be treated with either AZD6244 or pemetrexed Treatment will be continued for as long as patients receive clinical benefit
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None